Compare NBIX & AEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | AEG |
|---|---|---|
| Founded | 1992 | 1983 |
| Country | United States | Netherlands |
| Employees | N/A | 15304 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.7B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | AEG |
|---|---|---|
| Price | $156.33 | $8.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 1 |
| Target Price | ★ $180.91 | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 4.4M |
| Earning Date | 05-05-2026 | 02-09-2023 |
| Dividend Yield | N/A | ★ 4.68% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | $83.51 | ★ $7.91 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $6.68 |
| 52 Week High | $169.57 | $8.81 |
| Indicator | NBIX | AEG |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 59.12 |
| Support Level | $153.30 | $8.17 |
| Resistance Level | $160.08 | $8.81 |
| Average True Range (ATR) | 5.25 | 0.11 |
| MACD | -1.33 | 0.00 |
| Stochastic Oscillator | 14.33 | 85.59 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.